The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Treatment - If you take part in this trial you will be treated for about 10 weeks. You will receive an injection of Allovectin-7® by needle, directly into one or more selected tumors once a week for the first six weeks. The injections may be given in a doctor's office. During a four-week observation period, your disease will be measured to see if the treatment is working. This will be done by general physical exams and scans (such as X-ray scans). Patients who show no sign of disease progression may be offered an option to repeat this treatment course.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Masking
NONE
Enrollment
133
Arizona Cancer Center
Tucson, Arizona, United States
University of Arkansas Cancer Research Center
Little Rock, Arkansas, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
University of California, San Francisco
San Francisco, California, United States
University of Colorado Cancer Center
Denver, Colorado, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Louisiana State University Medical Center
New Orleans, Louisiana, United States
Hematology Oncology Associates of Baltimore
Baltimore, Maryland, United States
North Memorial Health Care
Robbinsdale, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
...and 6 more locations